Raymond James & Associates »

Trevi Therapeutics shares owned by Raymond James & Associates

Quarter-by-quarter ownership of Trevi Therapeutics (TRVI) shares owned by Raymond James & Associates from 13F filings

Historical chart of Raymond James & Associates investment in Trevi Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Trevi Therapeutics held by Raymond James & Associates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Trevi Therapeutics by Raymond James & Associates

Quarter filed Position value Share count Share price at filing
2024-03-31 $35k 10k 3.45

More positions owned by Raymond James & Associates

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr Core Us Aggbd Et (AGG)
Microsoft Corporation (MSFT)
Apple (AAPL)
Amazon (AMZN)
NVIDIA Corporation (NVDA)
Ishares Tr Core Msci Eafe (IEFA)
JPMorgan Chase & Co. (JPM)
Broadcom (AVGO)
Alphabet Cap Stk Cl A (GOOGL)
Home Depot (HD)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ishares Tr Msci Usa Min Vol (USMV)
Merck & Co (MRK)
Eaton Corp SHS (ETN)

View all positions for Raymond James & Associates

Top funds holding Trevi Therapeutics

NEA Management Company
Frazier Life Sciences Management
Rubric Capital Management
Viking Global Investors
VR Adviser
Opaleye Management
Vanguard Group
Checkpoint Capital
Tejara Capital
MAI Wealth Advisors
Rosalind Advisors
Landscape Capital Management
Tang Capital Management
Citadel Advisors
J. Goldman & Co

View all funds holding Trevi Therapeutics